Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson’s disease

Código QR

Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson’s disease

Hidetomo Murakami, Tetsuhito Nohara, Hidenobu Shozawa, Yoshiyuki Owan, Takeshi Kuroda, Satoshi Yano, Machiko Kezuka, Mitsuru Kawamura, Kenjiro Ono Department of Neurology, School of Medicine, Showa University, Tokyo, Japan Background: Effects of dopaminergic medication on executive function in pat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Murakami H, Nohara T, Shozawa H, Owan Y, Kuroda T, Yano S, Kezuka M, Kawamura M, Ono K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Parkinson disease Executive function Motor disorders Dopaminergic drug Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/4c416acae88b43c083837cf66669186a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Neuroprotective Potential of Polydatin Against Motor Abnormalities and Dopaminergic Neuronal Loss in Rotenone Induced Parkinson Model
por: Ahmed,Muhammad Rashid, et al.
Publicado: (2018)

TFE3-Mediated Autophagy is Involved in Dopaminergic Neurodegeneration in Parkinson’s Disease
por: Xin He, et al.
Publicado: (2021)

Triggering Receptor Expressed on Myeloid Cells 2 Protects Dopaminergic Neurons by Promoting Autophagy in the Inflammatory Pathogenesis of Parkinson’s Disease
por: Wei Huang, et al.
Publicado: (2021)

Spatial disorientation and executive dysfunction in elderly nondemented patients with Parkinson’s disease
por: Cammisuli DM, et al.
Publicado: (2018)

Evaluation of the Association Between Serum Levels of Testosterone and Prolactin With 6- Hydroxydopamine- Induced Parkinsonism in Male Rats
por: Roghaieh Razaghi, et al.
Publicado: (2021)

Fyn kinase regulates dopaminergic neuronal apoptosis in animal and cell models of high glucose (HG) treatment
por: Changhong Tan, et al.
Publicado: (2021)

Neurophysiological Predictors of Response to Medication in Parkinson's Disease
por: Saša R. Filipović, et al.
Publicado: (2021)

Is Generalized and Segmental Dystonia Accompanied by Impairments in the Dopaminergic System?
por: Jun Ikezawa, et al.
Publicado: (2021)

Autophagy Inhibitor 3-Methyladenine could not Modulate Rotenone Neurotoxicity in Primary Mesencephalic Cell Culture
por: Radad,Khaled, et al.
Publicado: (2020)

Affective theory of mind in Parkinson’s disease: the effect of cognitive performance
por: Romosan AM, et al.
Publicado: (2019)

Role of G Protein-Coupled Receptors in Microglial Activation: Implication in Parkinson’s Disease
por: Chao Gu, et al.
Publicado: (2021)

SYNTHESIS OF 1-BENZYL-3-[4-(ARYL-1-PIPERAZINYL) CARBONYL]-1H-INDOLES: NOVEL LIGANDS WITH POTENTIAL D4 DOPAMINERGIC ACTIVITY
por: PESSOA-MAHANA,HERNÁN, et al.
Publicado: (2011)

Dopaminergic pathway and primary visual cortex are involved in the freezing of gait in Parkinson’s disease: a PET-CT study
por: Zhou Y, et al.
Publicado: (2019)

Conditional disruption of AMP kinase in dopaminergic neurons promotes Parkinson's disease-associated phenotypes in vivo
por: Liting Hang, et al.
Publicado: (2021)

Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study
por: Schettino C, et al.
Publicado: (2016)

The Neuro-Protective Effects of the TSPO Ligands CB86 and CB204 on 6-OHDA-Induced PC12 Cell Death as an In Vitro Model for Parkinson’s Disease
por: Sheelu Monga, et al.
Publicado: (2021)

Atypical antipsychotics for Parkinson’s disease psychosis: a systematic review and meta-analysis
por: Zhang H, et al.
Publicado: (2019)

The role of rasagiline in the treatment of Parkinson’s disease
por: Julie Leegwater-Kim, et al.
Publicado: (2010)

Parkinson's disease

Odor selectivity of hyposmia and cognitive impairment in patients with Parkinson’s disease
por: Mao CJ, et al.
Publicado: (2017)

Cytological and cytometric analysis of oral mucosa in patients with Alzheimer’s and Parkinson’s disease
por: Kose Ozlece H, et al.
Publicado: (2018)

Neuropsychiatric symptoms in untreated Parkinson’s disease
por: Szatmari S, et al.
Publicado: (2017)

Astrocytes and retrograde degeneration of nigrostriatal dopaminergic neurons in Parkinson’s disease: removing axonal debris
por: Ingrid Morales, et al.
Publicado: (2021)

Systematic review on strength training in Parkinson’s disease: an unsolved question
por: Ramazzina I, et al.
Publicado: (2017)

Clinical study of the effects of deep brain stimulation on urinary dysfunctions in patients with Parkinson’s disease
por: Zong H, et al.
Publicado: (2019)

Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin
por: Combs BL, et al.
Publicado: (2017)

Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
por: Werner Poewe, et al.
Publicado: (2010)

Parkinson’s disease managing reversible neurodegeneration
por: Hinz M, et al.
Publicado: (2016)

Neuroprotective effect and mechanism of baicalin on Parkinson’s disease model induced by 6-OHDA
por: Tu L, et al.
Publicado: (2020)

Sleep apnea leading to Parkinson’s disease – an important association
por: Shafqat MN, et al.
Publicado: (2017)

Parkinson’s Disease Managing Reversible Neurodegeneration [Retraction]
por: Hinz M, et al.
Publicado: (2020)

Psychosis in parkinsonism: an unorthodox approach
por: Onofrj M, et al.
Publicado: (2017)

Journal of Parkinson's disease

Altered emotional recognition and expression in patients with Parkinson’s disease
por: Jin Y, et al.
Publicado: (2017)

Parkinson’s Disease Managing Reversible Neurodegeneration [Expression of Concern]
por: Hinz M, et al.
Publicado: (2020)

A practical method for the detection of freezing of gait in patients with Parkinson’s disease
por: Kwon Y, et al.
Publicado: (2014)

Different protocols for analyzing behavior and adaptability in obstacle crossing in Parkinson’s disease
por: Mollaei N, et al.
Publicado: (2017)

Elevated circulating magnesium levels in patients with Parkinson’s disease: a meta-analysis
por: Jin X, et al.
Publicado: (2018)

Impact of Supporting People with Advanced Parkinson’s Disease on Carer’s Quality of Life and Burden
por: Modugno N, et al.
Publicado: (2020)

The association between CD157/BST1 polymorphisms and the susceptibility of Parkinson’s disease: a meta-analysis
por: Li J, et al.
Publicado: (2019)